Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK to review gene therapy work amid leukaemia fears:

This article was originally published in Clinica

Executive Summary

The UK's Gene Therapy Advisory Committee (GTAC) has today (October 3 2002) announced that it is to review gene therapy research, after a French patient undergoing an X-SCID trial developed leukaemia. The French trial is based at the Necker Hospital in Paris. There are two X-SCID trials underway in the UK, based at Great Ormond Street Hospital, London. The GTAC has stopped short of halting these, but has announced that it will monitor developments, review similar trials and issue advice accordingly. In its 2000 annual report, the GTAC reported a high-degree of success in trials for severe combined immunodeficiency (SCID). That year there was a three-fold increase in UK-based gene therapy trials (see Clinica No 990, p 3). Worldwide there are 636 completed, ongoing or pending gene therapy trials.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT068395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel